CytomX CEO Nancy Stagliano said that following closely on the recent Series B financing, they believe these grants are another validation of the potential of their site-directed antibody development programs.
"We are very appreciative of the support provided by these grants and will use the funds to further advance our promising oncology program toward the clinic and achieve our mission of creating safer, more effective antibody therapies," Stagliano said said.